Protalix BioTherapeutics, Inc.

PLX · NYSE American

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.9%

Institutions18.4%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$52.74M	$53.40M	$65.49M	$47.64M	$38.35M	$62.90M	$54.69M	$34.24M	$19.24M	$9.20M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	$26.99M	$24.32M	$22.98M	$19.59M	$16.35M	$10.87M	$10.89M	$9.30M	$15.23M	$8.40M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	–	–	–	–	–	–	–	–	$4.01M	$801000
Gross profit as a percentage of revenue.	–	–	–	–	–	–	–	–	20.8%	8.7%
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$5.50M	$3.92M	$10.46M	-$13.01M	-$20.46M	$2.71M	-$10.72M	-$19.31M	-$36.35M	-$33.16M
Operating income as a percentage of revenue.	-10.4%	7.3%	16.0%	-27.3%	-53.4%	4.3%	-19.6%	-56.4%	-188.9%	-360.5%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$6.60M	$2.93M	$8.31M	-$14.93M	-$27.58M	-$6.52M	-$18.28M	-$26.46M	-$85.28M	-$29.36M
Net income divided by the number of shares outstanding — profit attributable to each share.	$0.00	$0.00	$0.00	$0.00	$-0.62	$-0.22	$-1.00	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$0.00	$0.00	$0.00	$0.00	$-0.62	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$14.68M	$19.76M	$23.63M	$17.11M	$38.98M	$18.27M	$17.79M	$37.81M	$51.16M	$63.28M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$82.35M	$73.42M	$84.43M	$55.79M	$73.67M	$67.93M	$45.39M	$61.13M	$72.21M	$82.25M
All of the company's interest-bearing borrowings, short and long term combined.	–	$0	$20.25M	–	–	$58.51M	$4.30M	–	$5.92M	$53.87M
Everything the company owes — debt, unpaid bills, and other obligations.	$34.12M	$30.21M	$50.87M	$66.43M	$79.70M	$94.97M	$115.71M	$114.01M	$103.51M	$92.20M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$48.23M	$43.21M	$33.57M	-$10.64M	-$6.04M	-$27.04M	-$70.32M	-$52.88M	-$31.29M	-$9.96M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$11.99M	$8.67M	-$1.32M	-$25.00M	-$10.29M	-$26.11M	-$19.36M	-$7.74M	-$9.99M	-$32.09M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$1.64M	$1.28M	$1.15M	$628000	$1.46M	$655000	$627000	$686000	$971000	$849000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$13.63M	$7.39M	-$2.47M	-$25.63M	-$11.74M	-$26.76M	-$19.98M	-$8.43M	-$10.96M	-$32.94M

	You	Peer avg
P/E	11.6	–
Revenue Growth	+27.1%	-0.5%
ROE	31.2%	-93.3%

Protalix BioTherapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison